Key statistics dashboard for KalVista Pharmaceuticals, Inc. (KALV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P.
Stock Data
| Price | $27.00 |
| Market Cap | $1.4B |
| Enterprise Value | $1.49B |
| Beta | -0.40 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -8.36 |
| Price / Book | -503.31 |
| P/S | 12.40 |
| EV/EBITDA | -12.74 |
| EV/Sales | 12.88 |
| EV/FCF | -26.39 |
| P/FCF | -25.42 |
| Earnings Yield | -10.15% |
| FCF Yield | -3.93% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 92.03% |
| EBIT Margin | -102.42% |
| EBITDA Margin | -101.07% |
| Operating Margin | -120.80% |
| Net Margin | -119.44% |
| Return on Equity | -1057.44% |
| Return on Assets | -41.28% |
| Return on Invested Capital | -46.81% |
| Return on Capital Employed | -50.36% |
Financial Health
| Current Ratio | 5.58 |
| Quick Ratio | 5.52 |
| Cash Ratio | 4.00 |
| Debt / Equity | -104.83 |
| Debt / Assets | 84.74% |
| Net Debt / EBITDA | -0.47 |
| Interest Coverage | -6.22 |
Per-Share Data
| Revenue per share | 2.29 |
| Book Value per share | -0.05 |
| Cash per share | 5.94 |
| FCF per share | -1.12 |
| Tangible Book Value per share | -0.05 |
| Dividend per share | 0.00 |
Related companies: COGT · KNSA · KRYS · KURA · LRMR · PTGX · SRRK
Explore sector: Healthcare · Biotechnology
More sections of KALV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks